Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Brief Summary: The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.


Options:
A: Arm Label: Bevacizumab plus chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab | Arm Label: Atezolizumab plus bevacizumab plus chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab, Drug: Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy, Bevacizumab plus chemotherapy | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab plus bevacizumab plus chemotherapy
B: Arm Label: Nivolumab and Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Pemetrexed and Cisplatin (or Carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Carboplatin | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Ipilimumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab and Ipilimumab | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed and Cisplatin (or Carboplatin) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed and Cisplatin (or Carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pemetrexed and Cisplatin (or Carboplatin)
C: Arm Label: Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q2W (Part B); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): MEL: Pembrolizumab 10 mg/kg Q2W (Part B), MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D), MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D), NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F), NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F), NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled), Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1), Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)
D: Arm Label: Drug: ADI-PEG 20 plus Pem Platinum; Type: EXPERIMENTAL; Interventions: Drug: ADI-PEG 20 plus Pem Platinum | Arm Label: Drug: Placebo plus Pem Platinum; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo plus Pem Platinum | Intervention Type: DRUG; Name: ADI-PEG 20 plus Pem Platinum; Assigned to Arm(s): Drug: ADI-PEG 20 plus Pem Platinum | Intervention Type: OTHER; Name: Placebo plus Pem Platinum; Assigned to Arm(s): Drug: Placebo plus Pem Platinum

Answer: B